期刊文献+

EGFR-TKI治疗非小细胞肺癌脑转移的研究进展 被引量:8

在线阅读 下载PDF
导出
摘要 表皮生长因子-酪氨酸激酶抑制剂(EGFR-TKI)通过在细胞内与三磷酸腺苷竞争结合酪氨酸激酶的胞内区催化部分,抑制磷酸化反应,阻止向下游传达增殖信号,具有抑制癌细胞增殖的作用。基础研究及临床实验均显示EGFR-TKI可部分透过血脑屏障〔1〕,将其应用于脑转移癌的治疗成为新的研究热点。EGFR基因突变曾被证实在多步致癌过程中就已形成且可能与转移到脑有关〔2〕,
出处 《中国老年学杂志》 CAS CSCD 北大核心 2016年第20期5213-5215,共3页 Chinese Journal of Gerontology
作者简介 孙文宇(1991-),女,硕士,主要从事肿瘤的靶向治疗研究。 通讯作者:马克威(1968-),男,教授,硕士生导师,主要从事肿瘤细胞信号传导通路的调控研究。
  • 相关文献

参考文献3

二级参考文献22

  • 1Scagliotti GV, Parikh P, yon Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with ad- vanced-stage non-small-cell lung cancer [J]. J Clin Oncol, 2008,26(21):3543-3551.
  • 2Chen AM,Jahan TM,Jablons DM,et al. Risk of cerebral metastases and neurological death after pathological com- plete response to neoadjuvant therapy for locally advanced non-small cell lung cancer:clinical implications for the subsequent management of the brain[J]. Cancer,2007,109 (8): 1668-1675.
  • 3Rosell R, Moran T,Queralt C,et al. Screening for epider- mal growth factor receptor mutations in lung cancer[J]. N Engl J Med,2009,361(10):958-967.
  • 4Maemondo M,Inoue A,Kobayashi K,et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. N Engl J Med,2010,362(25):2380-2388.
  • 5Wu C ,Li YL,Wang ZM,et al. Gefitinib as palliative therapy for lung adenoearcinoma metastatic to the brain [J]. Lung Cancer, 2007,57(3):359-364.
  • 6Kim JE,Lee DH,Choi Y,et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis[J]. Lung Can- cer, 2009,65(3):351-354.
  • 7Berger LA ,Riesenberg H ,Bokemeyer C ,et al. CNS metas- tases in non-small-cell lung cancer:current role of EGFR- TKI therapy and future perspectives[J]. Lung Cancer, 2013,80(3):242-248.
  • 8Heon S,Yeap BY, Britt GJ,et al. Development of central nervous system metastases in patients with advanced non- small cell lung cancer and somatic EGFR mutations treat- ed with gefitinib or erlotinib[J]. Clin Cancer Res,2010, 16 (23):5873-5882.
  • 9Kim ST,Lee J,Kim JH,et al.Comparison of gefitinib ver- sus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy[J]. Cancer, 2010,116 (12):3025-3033.
  • 10Gaspar LE,Chansky K,Albain KS,et al. Time from treat- ment to subsequent diagnosis of brain metastases in stage Ⅲ non-small-cell lung cancer:a retrospective review by the Southwest Oncology Group[J]. J Clin Oncol,2005,23 (13):2955-2961.

共引文献17

同被引文献67

引证文献8

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部